Signed in as:
filler@godaddy.com
driven by science
Genetic analyses for cancer clinical trials
We are committed to improving prevalent civilization-related diseases, including cancer, through specialized genetic analysis services for clinical trials. Our approach strategically matches patients to appropriate clinical trials based on their DNA, employing stringent genetic inclusion and exclusion criteria to optimize outcomes (personalized medicine).
Our research incorporates high-throughput genetic methods, AI-driven big data analysis, and advanced biotechnologies at our dedicated science hub. We utilize DNA technology to enhance health, prevent diseases, and combat disorders. Discover how our innovative methods can tailor healthcare to your genetic blueprint, ensuring more effective and targeted treatments.
Our activities align with the US National Interest as described in the projects:
NIH about the Cancer Moonshot Project
The Cancer Genome Atlas Program (TCGA)
NIH Clinical Research Trials and You
Clinical Trials by American Cancer Scociety
Nutrigenomics & pharmacogenomics
We support human health and longevity through specialized genetic analysis services for nutrigenomics—an innovative field that explores the interaction between nutrition and genes. This science seeks to understand how our diet influences our health at the molecular level by elucidating how specific nutrients or dietary patterns can affect gene expression, ultimately impacting disease prevention and management. Nutrigenomics aims to personalize nutritional recommendations by studying individual genetic variations, optimizing health outcomes based on genetic makeup. This personalized approach not only aids in managing and preventing lifestyle-related diseases such as diabetes and obesity but also enhances overall well-being by tailoring dietary strategies to suit individual needs.
Additionally, we integrate pharmacogenomics, which analyzes how genes affect a person's response to drugs. This field allows for the customization of drug therapies to each individual's genetic profile, enhancing drug efficacy and safety, reducing adverse effects, and ensuring more precise and effective treatments. By combining insights from both nutrigenomics and pharmacogenomics, we provide a comprehensive approach to personalized medicine that promotes optimal health and treatment outcomes.
Health-Supporting GMOs
We proudly support the development of new biotechnologies for health-supporting GMOs, which enhance the nutritional content of food crops and transform them into superfoods. Traditional genetic engineering, including plant transformation along with new CRISPR genome-editing methods, not only revolutionizes agricultural biotechnology but also enables the design of products that may play a major role in preventing civilization-related diseases such as cancer and cardiovascular diseases.
Nature has been refining genetic modifications through millions of years of random mutations, natural selection, and adaptation, ultimately leading to the development of diverse, improved organisms, including humans, along with our ability to accelerate this process. However, this acceleration requires special caution, controls, and safety protocols, including genetic testing that we can deliver. By leveraging safe GMO technology, we uphold this legacy to support sustainable agricultural solutions that can promote human health and longevity while preserving nature.
Innovations such as "Golden Rice," producing beta-carotene, address vitamin A deficiencies in staple diets across the globe and was designed to save lives.
Developments in transgenic tomato plants to produce beneficial phytochemicals such as anthocyanins, betalains or β-carotene and lycopene represent significant strides in food science. Tomatoes are the most popular vegetable worldwide, with an annual production of about 186 million metric tons.
Notably, anthocyanin-producing purple tomatoes, developed by Cathie Martin's team, have demonstrated potential health benefits, including extending the lifespan of cancer-susceptible mice, as highlighted by the John Innes Centre. Moreover, the anthocyanin-expressing Purple Tomato from Norfolk Healthy Produce was approved by the FDA for US home gardeners in 2024.
Furthermore, Sylvestre Marillonnet's research into tomatoes engineered to produce betalains (, which are naturally produced by beetroots and known for their anti-inflammatory and antioxidant properties, continues to gain attention. The betalains have been found to reduce the risk of some cancers and cardiovascular diseases.
Our commitment to assisting in the development of pioneering biotechnologies underscores our dedication to improving global health through enhanced diets and promoting sustainable agricultural practices.